Acamprosate and baclofen were not effective in the treatment of pathological gambling: Preliminary blind rater comparison study

Frontiers in Psychiatry

Volumn 2, Issue JUN, 2011, Pages

  Dannon, Pinhas N ^a   Rosenberg, Oded ^a   Schoenfeld, Netta ^a   Kotler, Moshe ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Acamprosate; Baclofen; Behavioral addiction; GABA; Pathological gambling

Indexed keywords

ACAMPROSATE; BACLOFEN;

ABSTINENCE; ADULT; AGED; APATHY; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; HAMILTON SCALE; HUMAN; MALE; MUSCLE RIGIDITY; MYALGIA; NAUSEA; PATHOLOGICAL GAMBLING; SEMI STRUCTURED INTERVIEW; SIDE EFFECT; VISUAL ANALOG SCALE; VOMITING; WEAKNESS;

EID: 84866156100     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2011.00033     Document Type: Article

References (23)

1. Addolorato, G., Leggio, L., Agabio, R., Colombo, G., and Gasbarrini, G. (2006). Baclofen: a new drug for the treatment of alcohol dependence. Int. J. Clin. Pract. 60, 1003-1008.
2. Addolorato, G., Leggio, L., Cardone, S., Ferrulli, A., and Gasbarrini, G. (2009). Role of the GABA (B) receptor system in alcoholism and stress: focus on clinical studies and treatment perspectives. Alcohol 43, 559-563.
3. American Psychiatric Association. (2000). Diagnostic and Statistical Manual of Mental Disorders, 4th Edn. Washington, DC: American Psychiatric Association.
4. Black, D. (2004). An open-label trial of bupropion in the treatment of pathological gambling. J. Clin. Psychopharmacol. 24, 108-109.
5. Blanco, C, Petkova, E., Ibanez, A., and Saiz-Ruiz, J. (2002). A pilot placebo-controlled study of fluvoxamine for pathological gambling. Ann. Clin. Psychiatry 14, 9-15.
6. Boothby, L. A., and Doering, P. L. (2005). Acamprosate for the treatment of alcohol dependence. Clin. Ther. 27, 695-714.
7. Dannon, P. N., Lowengrub, K., Gonopolski, Y., Musin, E., and Kotler, M. (2006). Pathological gambling: a review of phenome-nological models and treatment modalities for an under recognized psychiatric disorder. Prim Care Companion J. Clin. Psychiatry 8, 334-339.
8. Dannon, P. N., Lowengrub, K., Musin, E., Gonopolski, Y., and Kotler, M. (2005a). Sustained release Bupropion versus naltrexone in the treatment of pathological gambling. J. Clin. Psychopharmacol. 25, 593-596.
9. Dannon, P. N., Lowengrub, K., Gonopolski, Y, Musin, E., and Kotler, M. (2005b). Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study. Clin. Neuropharmacol. 28, 6-10.
10. Dannon, P. N., Lowengrub, K., Musin, E., Gonoposki, Y, and Kotler, M. (2005c). Sustained release bupropion in the treatment of SSRI no responder pathological gamblers: pilot study and review of the literature. Therapy 2, 753-759.
11. Dannon, P. N., Lowengrub, K., Musin, E., Gonopolski, Y, and Kotler, M. (2007). 12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study. J. Clin. Psychopharmacol. 27, 620-624.
12. Grant, J. E., Kim, S. W., Potenza, M. N., Blanco, C, Ibanez, A., Stevens, L., Hektner, J. M., and Zaninelli. R. (2003). Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial. Int. Clin. Psychopharmacol. 18, 243- 249.
13. Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare Publication (ADM), 76-338.
14. Hamilton, M. (1959). The assessment of anxiety states by rating. Br. J. Med. Psychol. 32, 50-55.
15. Hamilton, M. (1960). A rating scale for depression. J. Neurol. Neurosurg. Psychiatr. 23, 56-62.
16. Hollander, E., DeCaria, C. M., Finkell, J. N., Begazab, T., Wongab, C. M., Cartwrightab, C. (2000). A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. Biol. Psychiatry 47, 813-817.
17. Iancu, I., Lowengrub, K., Dembinsky, Y., Kotler, M., and Dannon, P. N. (2008). Pathological gambling: an update on neuropath physiology and pharmacotherapy. CNS Drugs 22, 123-138.
18. Kim, S. W., Grant, J. E., Adson, D. E., Shin, Y. C, and Zaninelli, R. (2002). A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. J. Clin. Psychiatry 63,501-507.
19. Kim, S. W., and Grant, J. E. (2001). An open naltrexone treatment study in pathological gambling disorder. Int. Clin. Psychopharmacol. 16,285-289.
20. Kim, S. W., Grant, J. E., Adson, D. E., and Shin, YC. (2001). Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol. Psychiatry 49, 914-921.
21. Leisure,H., and Blume, S. B. (1987). The South Oaks gambling screen (the SOGS): a new instrument for the identification of pathological gamblers. Am. J. Psychiatry 144, 1184-1188.
22. Raj, Y P. (2010). Gambling on acamprosate: a case report. J. Clin. Psychiatry 71, 1245-1246.
23. World Health Organization. (1992). The ICD-10 Classification of Mental and Behavioral Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization.